Stealth BioTherapeutics to Present at Upcoming September Virtual Investor Conferences

Rhea-AI Summary

Stealth BioTherapeutics Corp (MITO) announced that CEO Reenie McCarthy will present at two virtual investor conferences in September 2021. The presentations will include a pre-recorded segment at the H.C. Wainwright 23rd Annual Global Investment Conference, available on-demand starting September 13, and a live fireside chat at the Cantor Global Healthcare Conference on September 30.

Stealth focuses on developing therapies for mitochondrial dysfunction, with candidates like elamipretide targeting rare diseases and ophthalmic conditions.

BOSTON, Sept. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at two upcoming virtual investor conferences in September:

• H.C. Wainwright 23rd Annual Global Investment Conference. Pre-recorded presentation available for on-demand viewing starting on Monday, September 13 at 7:00 a.m. ET.
• Cantor Global Healthcare Conference. Fireside chat on Thursday, September 30 at 11:20 a.m. ET.

A live audio webcast of the presentations will be available on the Investors & News section of Stealth's website at https://investor.stealthbt.com/. A replay of the webcasts will be archived on Stealth's website for 30 days following the event.

About Stealth

We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth syndrome, Duchenne muscular dystrophy and Friedreich's ataxia, rare mitochondrial diseases entailing nuclear DNA mutations, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration and Leber's hereditary optic neuropathy. We are evaluating our second-generation clinical-stage candidate, SBT-272, and our new series of small molecules, SBT-550, for rare neurological disease indications following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria.

Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-present-at-upcoming-september-virtual-investor-conferences-301370687.html

SOURCE Stealth BioTherapeutics Inc.

FAQ

When is Stealth BioTherapeutics presenting at the H.C. Wainwright Conference?

Stealth BioTherapeutics will have a pre-recorded presentation available for on-demand viewing starting on September 13, 2021, at 7:00 a.m. ET.

When will the Cantor Global Healthcare Conference take place?

The Cantor Global Healthcare Conference will feature Stealth's CEO in a live fireside chat on September 30, 2021, at 11:20 a.m. ET.

What is the focus of Stealth BioTherapeutics?

Stealth BioTherapeutics is focused on developing novel therapies for diseases caused by mitochondrial dysfunction.

What is elamipretide?

Elamipretide is Stealth's lead product candidate aimed at treating rare metabolic cardiomyopathies and ophthalmic diseases related to mitochondrial dysfunction.

How can I access the investor presentations?

The live audio webcasts of the presentations will be available on the Investors & News section of Stealth's website, and replays will be archived for 30 days post-event.